umu.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Andersson-Evelönn, Emma
Alternative names
Publications (8 of 8) Show all publications
Andersson-Evelönn, E. (2020). DNA methylation as a prognostic marker in clear cell Renal Cell Carcinoma. (Doctoral dissertation). Umeå: Umeå universitet
Open this publication in new window or tab >>DNA methylation as a prognostic marker in clear cell Renal Cell Carcinoma
2020 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma worldwide. Metastatic ccRCC is correlated to poor prognosis whereas non-metastatic disease has a 5-year survival rate up to 90%. Due to increased accessibility to different types of diagnostic imaging the frequency of metastatic ccRCC at diagnosis has decreased since the beginning of the 21st century. This has led to an earlier detection of primary tumors before patients present symptoms. However, 20-30% of the non-metastatic patients at diagnosis will progress and metastasize within five years of primary nephrectomy. Identifying patients at high risk of tumor progression at an early stage after diagnosis is of importance to improve outcome and survival. Currently, in Sweden, the Mayo scoring system is used to divide tumors into low, intermediate or high risk for tumor progression.

DNA methylation has been associated with tumor development and progression in different malignancies. In this thesis, Illumina Infinium HumanMeth27 BeadChip Arrays and Human Meth450K BeadChip Arrays have been used to evaluate the relationship between methylation and clinicopathological variables as well as ccRCC outcome in 45 and 115 patients.

Our studies identified an association between higher level of promoter-associated DNA methylation and clinicopathological variables in ccRCC. There was a significant stepwise increase of average methylation from tumor-free tissue, via non-metastatic tumors to metastatic disease. Cluster analysis divided patients into two distinct groups that differed in average methylation levels, TNM stage, Fuhrman nuclear grade, tumor size, survival and tumor progression. We also presented two prognostic classifiers for non-metastatic tumors; the promoter methylation classifier (PMC) panel and the triple classifier. The PMC panel divided tumors depending on the methylation level, PMC low or PMC high, with significantly worse prognosis in the PMC high group. This data was verified in an independent, publically available cohort. The triple classifier was created using a combination of clinicopathological variables, previously identified CpGs biomarkers and a novel cluster analysis approach (Directed Cluster Analysis). The triple classifier had a higher specificity compared to the clinically used Mayo scoring system and predicted tumor progression with higher accuracy at a fixed sensitivity.

The identification of two epigenetic classifiers that predicted outcome in non-metastatic ccRCC further establishes the role of DNA methylation as a prognostic marker. This knowledge can contribute to identification of patients with a high risk of tumor progression and can be of importance in the decision regarding adjuvant treatment post-nephrectomy.

Abstract [sv]

Populärvetenskaplig sammanfattning

Klarcellig njurcancer är den vanligaste form av njurcancer. I Sverige diagnostiseras ca 1 000 individer årligen med sjukdomen. Idag upptäcks ofta njurcancer när patienter undersöks med bilddiagnostik av buken av andra anledningar, exempelvis vid oklar buksmärta och vid trauma. Detta gör att tumörerna upptäcks innan de hunnit ge symtom och andelen patienter med spridd sjukdom vid diagnos är under 20%, jämfört med över 30% i början av milleniet.

Den enda botande behandling som finns för njurcancer är total eller partiell nefrektomi, vilket innebär att hela njuren eller delen av njuren med tumör opereras bort. Om sjukdomen upptäcks tidigt, innan den hunnit sprida sig till kringliggande organ, är prognosen god och 90% av patienterna lever minst fem år efter diagnos. Är sjukdomen spridd vid diagnos finns det idag behandlingar som förlänger överlevnadstiden, och ny immunbehandling som också kan bota sjukdomen.

Även om klarcellig njurcancer som är begränsad till njuren botas när tumören avlägsnas är det ungefär en tredjedel av dessa patienter som drabbas av en ny njurtumör eller spridning till andra organ inom fem år efter diagnos. Behovet av att identifiera dessa patienter är stort när de är i behov av tilläggsbehandling. Idag utgår klinikerna från hur tumören ser ut när de bestämmer hur patienterna ska följas efter kirurgi, vid karakteristika som talar för en hög risk för spridning följs patienterna tätare och under längre tid.

Genom att analysera hur ccRCC tumörer ser ut på cellnivå har skillnader i genuttryck och DNA-sekvenser kunna identifieras. Att utnyttja dessa skillnader är viktiga för att identifiera tumörer med ökad risk för spridning.

I min avhandling har vi analyserat DNA metylering i klarcellig njurcancer vid diagnos. DNA metylering är en epigenetisk förändring, en förändring på DNA nivå som inte påverkar DNA sekvensen men kan påverkar vilka gener som uttrycks i cellerna. Nivåerna av DNA metylering skiljer sig mellan olika prognostiska grupper ccRCC. De tumörer som vid diagnos redan spridit sig till kringliggande organ har en högre grad av metylering jämfört med de tumörer som växer endast i njuren. Vi har även kunnat visa på skillnader mellan de lokala tumörer som senare sprids. Detta gör att DNA metylering kan användas som prognostisk markör i ccRCC.

Place, publisher, year, edition, pages
Umeå: Umeå universitet, 2020. p. 50
Series
Umeå University medical dissertations, ISSN 0346-6612 ; 2066
Keywords
Clear cell renal cell carcinoma, DNA methylation, Prognosis, Clinical outcome, Epigenetic classifiers
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-167591 (URN)978-91-7855-166-8 (ISBN)978-91-7855-165-1 (ISBN)
Public defence
2020-02-21, Stora Hörsalen, byggnad 5B, Norrlands universitetssjukhus, Umeå, 09:00 (English)
Opponent
Supervisors
Available from: 2020-01-31 Created: 2020-01-31 Last updated: 2020-02-04Bibliographically approved
Andersson Evelönn, E., Landfors, M., Haider, Z., Köhn, L., Ljungberg, B., Roos, G. & Degerman, S. (2019). DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma. BMC Cancer, 19, Article ID 65.
Open this publication in new window or tab >>DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma
Show others...
2019 (English)In: BMC Cancer, ISSN 1471-2407, E-ISSN 1471-2407, Vol. 19, article id 65Article in journal (Refereed) Published
Abstract [en]

Background: Clear cell renal cell carcinoma (ccRCC) is the most common subtype among renal cancer and is associated with poor prognosis if metastasized. Up to one third of patients with local disease at diagnosis will develop metastasis after nephrectomy, and there is a need for new molecular markers to identify patients with high risk of tumor progression. In the present study, we performed genome-wide promoter DNA methylation analysis at diagnosis to identify DNA methylation profiles associated with risk for progress.

Method: Diagnostic tissue samples from 115 ccRCC patients were analysed by Illumina HumanMethylation450K arrays and methylation status of 155,931 promoter associated CpGs were related to genetic aberrations, gene expression and clinicopathological parameters.

Results: The ccRCC samples separated into two clusters (cluster A/B) based on genome-wide promoter methylation status. The samples in these clusters differed in tumor diameter (p < 0.001), TNM stage (p < 0.001), morphological grade (p < 0.001), and patients outcome (5 year cancer specific survival (pCSS5yr) p < 0.001 and cumulative incidence of progress (pCIP5yr) p < 0.001. An integrated genomic and epigenomic analysis in the ccRCCs, revealed significant correlations between the total number of genetic aberrations and total number of hypermethylated CpGs (R = 0.435, p < 0.001), and predicted mitotic age (R = 0.407, p < 0.001). We identified a promoter methylation classifier (PMC) panel consisting of 172 differently methylated CpGs accompanying progress of disease. Classifying non-metastatic patients using the PMC panel showed that PMC high tumors had a worse prognosis compared with the PMC low tumors (pCIP5yr 38% vs. 8%, p = 0.001), which was confirmed in non-metastatic ccRCCs in the publically available TCGA-KIRC dataset (pCIP5yr 39% vs. 16%, p < 0.001).

Conclusion: DNA methylation analysis at diagnosis in ccRCC has the potential to improve outcome-prediction in non-metastatic patients at diagnosis.

Place, publisher, year, edition, pages
BioMed Central, 2019
Keywords
Clear cell renal cell carcinoma, DNA methylation, Prognosis, Genetic
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-155957 (URN)10.1186/s12885-019-5291-3 (DOI)000455576500013 ()30642274 (PubMedID)
Funder
The Kempe FoundationsSwedish Cancer SocietyVästerbotten County Council
Available from: 2019-02-08 Created: 2019-02-08 Last updated: 2020-03-27Bibliographically approved
Andersson Evelönn, E., Degerman, S., Köhn, L., Landfors, M., Ljungberg, B. & Roos, G. (2016). DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC). Tumor Biology, 37(8), 10219-10228
Open this publication in new window or tab >>DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC)
Show others...
2016 (English)In: Tumor Biology, ISSN 1010-4283, E-ISSN 1423-0380, Vol. 37, no 8, p. 10219-10228Article in journal (Refereed) Published
Abstract [en]

Epigenetic alterations in the methylome have been associated with tumor development and progression in renal cell carcinoma (RCC). In this study, 45 tumor samples, 12 tumor-free kidney cortex tissues, and 24 peripheral blood samples from patients with clear cell RCC (ccRCC) were analyzed by genome-wide promoter-directed methylation arrays and related to clinicopathological parameters. Unsupervised hierarchical clustering separated the tumors into two distinct methylation groups (clusters A and B), where cluster B had higher average methylation and increased number of hypermethylated CpG sites (CpGs). Furthermore, tumors in cluster B had, compared with cluster A, a larger tumor diameter (p = 0.033), a higher morphologic grade (p < 0.001), a higher tumor-node-metastasis (TNM) stage (p < 0.001), and a worse prognosis (p = 0.005). Higher TNM stage was correlated to an increase in average methylation level (p = 0.003) and number of hypermethylated CpGs (p = 0.003), whereas a number of hypomethylated CpGs were mainly unchanged. However, the predicted age of the tumors based on methylation profile did not correlate with TNM stage, morphological grade, or methylation cluster. Differently methylated (DM) genes (n = 840) in ccRCC samples compared with tumor-free kidney cortex samples were predominantly hypermethylated and a high proportion were identified as polycomb target genes. The DM genes were overrepresented by transcription factors, ligands, and receptors, indicating functional alterations of significance for ccRCC progression. To conclude, increased number of hypermethylated genes was associated with increased TNM stage of the tumors. DNA methylation classification of ccRCC tumor samples at diagnosis can serve as a clinically applicable prognostic marker in ccRCC.

Keywords
Clear cell renal cell carcinoma, DNA methylation, Survival, Predicted age, Polycomb target genes
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:umu:diva-126325 (URN)10.1007/s13277-016-4893-5 (DOI)000382672900022 ()26831665 (PubMedID)
Available from: 2016-10-27 Created: 2016-10-03 Last updated: 2020-03-27Bibliographically approved
Degerman, S., Landfors, M., Siwicki, J. K., Revie, J., Borssen, M., Evelönn, E., . . . Roos, G. (2014). Immortalization of T-Cells Is Accompanied by Gradual Changes in CpG Methylation Resulting in a Profile Resembling a Subset of T-Cell Leukemias. Neoplasia, 16(7), 606-615
Open this publication in new window or tab >>Immortalization of T-Cells Is Accompanied by Gradual Changes in CpG Methylation Resulting in a Profile Resembling a Subset of T-Cell Leukemias
Show others...
2014 (English)In: Neoplasia, ISSN 1522-8002, E-ISSN 1476-5586, Vol. 16, no 7, p. 606-615Article in journal (Refereed) Published
Abstract [en]

We have previously described gene expression changes during spontaneous immortalization of T-cells, thereby identifying cellular processes important for cell growth crisis escape and unlimited proliferation. Here, we analyze the same model to investigate the role of genome-wide methylation in the immortalization process at different time points pre-crisis and post-crisis using high-resolution arrays. We show that over time in culture there is an overall accumulation of methylation alterations, with preferential increased methylation close to transcription start sites (TSSs), islands, and shore regions. Methylation and gene expression alterations did not correlate for the majority of genes, but for the fraction that correlated, gain of methylation close to TSS was associated with decreased gene expression. Interestingly, the pattern of CpG site methylation observed in immortal T-cell cultures was similar to clinical T-cell acute lymphoblastic leukemia (T-ALL) samples classified as CpG island methylator phenotype positive. These sites were highly overrepresented by polycomb target genes and involved in developmental, cell adhesion, and cell signaling processes. The presence of non-random methylation events in in vitro immortalized T-cell cultures and diagnostic T-ALL samples indicates altered methylation of CpG sites with a possible role in malignant hematopoiesis.

National Category
Cancer and Oncology Medical Bioscience
Identifiers
urn:nbn:se:umu:diva-93242 (URN)10.1016/j.neo.2014.07.001 (DOI)000340553900006 ()
Funder
Swedish Research Council, Dnr 340-2013-5185EU, FP7, Seventh Framework Programme, 200950
Available from: 2014-12-22 Created: 2014-09-15 Last updated: 2018-06-07Bibliographically approved
Sitaram, R. T., Degerman, S., Ljungberg, B., Andersson, E., Oji, Y., Sugiyama, H., . . . Li, A.-H. (2010). Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways. British Journal of Cancer, 103(8), 1255-1262
Open this publication in new window or tab >>Wilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways
Show others...
2010 (English)In: British Journal of Cancer, ISSN 0007-0920, E-ISSN 1532-1827, Vol. 103, no 8, p. 1255-1262Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Wilms' tumour 1 (WT1) gene was discovered as a tumour suppressor gene. Later findings have suggested that WT1 also can be oncogenic. This complexity is partly explained by the fact that WT1 has a number of target genes.

METHOD: WT1 and its target gene human telomerase reverse transcriptase (hTERT) were analysed in clear cell renal cell carcinoma (ccRCC). In vitro experiments were performed to examine the functional link between WT1 and hTERT by overexpression of WT1 isoforms in the ccRCC cell line, TK-10.

RESULTS: WT1 demonstrated lower RNA expression in ccRCC compared with renal cortical tissue, whereas hTERT was increased, showing a negative correlation between WT1 and hTERT (P=0.005). These findings were experimentally confirmed in vitro. The WT1 generated effect on hTERT promoter activity seemed complex, as several negative regulators of hTERT transcription, such as SMAD3, JUN (AP-1) and ETS1, were activated by WT1 overexpression. Downregulation of potential positive hTERT regulators, such as cMyc, AP-2α, AP-2γ, IRF1, NFX1 and GM-CSF, were also observed. Chromatin immunoprecipitation analysis verified WT1 binding to the hTERT, cMyc and SMAD3 promoters.

CONCLUSION: The collected data strongly indicate multiple pathways for hTERT regulation by WT1 in ccRCC.

Keywords
renal cell carcinoma; WT1; hTERT; telomerase activity and pathways
Identifiers
urn:nbn:se:umu:diva-38095 (URN)10.1038/sj.bjc.6605878 (DOI)000283542900016 ()20842112 (PubMedID)
Available from: 2010-11-25 Created: 2010-11-24 Last updated: 2018-06-08Bibliographically approved
Andersson-Evelönn, E., Vidman, L., Källberg, D., Landfors, M., Liu, X., Ljungberg, B., . . . Rydén, P.Combining epigenetic and clinicopathological variables improves prognostic prediction in clear cell Renal Cell Carcinoma.
Open this publication in new window or tab >>Combining epigenetic and clinicopathological variables improves prognostic prediction in clear cell Renal Cell Carcinoma
Show others...
(English)Manuscript (preprint) (Other academic)
Keywords
DNA methylation, cancer, cluster analysis, classification, clear cell renal cell carcinoma
National Category
Cancer and Oncology Probability Theory and Statistics
Identifiers
urn:nbn:se:umu:diva-167269 (URN)
Available from: 2020-01-14 Created: 2020-01-14 Last updated: 2020-01-31Bibliographically approved
Li, X., Andersson-Evelönn, E., Wang, S., Raviprakash, T. S., Landfors, M., Ottosson, S., . . . Li, A.Prognostic Significance of Hypermethylation in the Promoter Region of the Wilms’ Tumour Gene 1 in Clear Cell Renal Cell Carcinoma.
Open this publication in new window or tab >>Prognostic Significance of Hypermethylation in the Promoter Region of the Wilms’ Tumour Gene 1 in Clear Cell Renal Cell Carcinoma
Show others...
(English)Manuscript (preprint) (Other academic)
National Category
Medical and Health Sciences
Identifiers
urn:nbn:se:umu:diva-103388 (URN)
Available from: 2015-05-21 Created: 2015-05-21 Last updated: 2018-06-07
Degerman, S., Borssen, M., Andersson, E., Chranowska, K. H., Siwicki, J. K. & Roos, G.Senescence bypass and immortalization of T cell cultures are linked to stepwise DNA methylation changes.
Open this publication in new window or tab >>Senescence bypass and immortalization of T cell cultures are linked to stepwise DNA methylation changes
Show others...
(English)Manuscript (preprint) (Other academic)
Keywords
T cell, CpG methylation, immortalization, telomerase, gene expression
National Category
Cell and Molecular Biology
Research subject
Pathology
Identifiers
urn:nbn:se:umu:diva-33451 (URN)
Available from: 2010-04-26 Created: 2010-04-26 Last updated: 2018-06-08Bibliographically approved
Organisations

Search in DiVA

Show all publications